Anesthetic Considerations in the Ovarian Hyperstimulation Syndrome

Background: The ovary hyperstimulation syndrome (OHSS) is a rare iatrogenic complication, associated with drugs used for induction of ovulation and follicular development during the in vitro fertilization procedures. Material and Methods: In this manuscript we performed a systematic review from medline, artemisa, pubmed, medigrafic, elsevier, current contents and the cochrane collaboration about ohss. A total of 112 articles were analyzed and finally 32 were included in the article. With the data we review the risk factors, etiology, pathophysiology, diagnosis, anesthetic techniques for the management and associated complications. Conclusion: With the increase in assisted reproductive procedures the OHSS syndrome is more prevalent and we have to know all about the risk factors, diagnosis and management for the integration of multidisciplinary groups that are going to treat those patients and prevent serious complications.

[1]  Enrique García,et al.  Anesthetic Considerations in the Ovarian Hyperstimulation Syndrome , 2018 .

[2]  D. Goulis,et al.  Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. , 2008, Fertility and sterility.

[3]  M. Payson,et al.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. , 2010, Fertility and sterility.

[4]  C. Simón,et al.  The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial† , 2010, Human reproduction.

[5]  M. Aboulghar.  Prevention of OHSS , 2009 .

[6]  Shee-Uan Chen,et al.  Ovarian Hyperstimulation Syndrome ( OHSS ) : New Strategies of Prevention and Treatment , 2008 .

[7]  Yu‐Shih Yang,et al.  Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. , 2007, Human reproduction.

[8]  C. Simón,et al.  Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. , 2007, Human reproduction.

[9]  C. Simón,et al.  Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. , 2007, The Journal of clinical endocrinology and metabolism.

[10]  V. E. L. E. Castro,et al.  Síndrome de hiperestimulación ovárica , 2007 .

[11]  C. Simón,et al.  Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. , 2006, Human reproduction.

[12]  C. Simón,et al.  Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. , 2003, Human reproduction.

[13]  A. Pellicer,et al.  Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS , 2003 .

[14]  U. Kaiser.  The pathogenesis of the ovarian hyperstimulation syndrome. , 2003, The New England journal of medicine.

[15]  A. Pellicer,et al.  New concepts in the understanding of the ovarian hyperstimulation syndrome , 2003, Current opinion in obstetrics & gynecology.

[16]  M. Aboulghar,et al.  Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. , 2003, Human reproduction update.

[17]  C. Simón,et al.  Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. , 2002, Endocrinology.

[18]  Serge Rozenberg,et al.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. , 2002, Human reproduction update.

[19]  S. Bhattacharya,et al.  Current management of ovarian hyperstimulation syndrome. , 2002, Hospital medicine.

[20]  Y. Soong,et al.  Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  E. Kubota,et al.  Adult respiratory distress syndrome as a manifestation of ovarian hyperstimulation syndrome , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[22]  A. Mercader,et al.  The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. , 1999, Fertility and sterility.

[23]  J. Schenker,et al.  The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. , 1997, Human reproduction.

[24]  A. Yajima,et al.  Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. , 1994, Fertility and sterility.

[25]  V. Wiwanitkit,et al.  Ovarian hyperstimulation syndrome , 1991, The Lancet.